Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05723692 · ClinicalTrials.gov registry record · Phase 1
A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers
A Phase 1 study, sponsored by AltruBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05723692 is a Phase 1 study that has completed, run by AltruBio. The registered enrollment target is 56 participants.
The verdict
NCT05723692, a Phase 1 study, has completed, sponsored by AltruBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of ALTB-268 in healthy volunteers.
Interventions
- OTHER Placebo
- BIOLOGICAL ALTB-268
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2023-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05723692
The ClinicalTrials.gov registry entry for NCT05723692 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AltruBio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05723692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05723692 about?
NCT05723692 is a clinical study titled "A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers". This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of ALTB-268 in healthy volunteers.
What is the current status of trial NCT05723692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2023-01-17. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT05723692?
The interventions under investigation include: Placebo (OTHER), ALTB-268 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05723692?
This trial is sponsored by AltruBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.